Recent Interviews

Alex Kent, Managing Director, Aspermont Limited

Alex Kent
Managing Director | Aspermont Limited
613 - 619 Wellington Street, WA, 6000 Perth (AUS)

+61 8 6263 9100

Aspermont shows the success of digitalization - Alex Kent has an agenda

Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities

Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen

18. August 2020 | 06:00 CET

BioNTech, CureVac, Valeo Pharma - who is the Covid-19 winner?

  • Covid-19
Photo credits:

The two German companies BioNTech and CureVac have already provided investors with a considerable boost in share prices. The companies have come into the public eye in recent months because they are working on a vaccine against Covid-19 and have already made great progress. Worldwide, these two companies belong to the elite in research and are a beacon of hope in the fight against the corona pandemic. While BioNTech has been listed on the stock exchange for some time, CureVac made its stock market debut last Friday - with success. Investors who have so far missed their entry in these companies should have Valeo Pharma at least on their watch list.

time to read: 1 minutes by Mario Hose



Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Vaccine promises sales boost

The capital market places great hope in German life science companies. The market value of BioNTech is now over USD 16 billion and the newcomer to the stock exchange, CureVac, has already achieved a market capitalisation of over EUR 11 billion. For those who have not yet joined, Valeo Pharma is probably the next big opportunity for share price gains. The market value of the Canadian pharmaceutical company is currently CAD 73 million, which is still a long way from the billion-dollar valuation of the two German companies that are already involved with Covid-19.

Market launch in Canada with Valeo Pharma?

It will certainly only be a matter of time before Valeo Pharma launches a Covid-19 product in Canada. The company is focused on launching drugs in Canada. Biotech companies that have developed a drug in other parts of the world can then launch it in the North American country with Valeo Pharma. The pharmaceutical company does not conduct any research itself and is focused on licensing, approval and distribution of new drugs - which saves time and money. The company's representatives have direct access to doctors and can present new drugs and their effects to decision-makers without wastage.

Expertise for the Canadian market

While European pharmaceutical companies focus on the huge US market and US companies supply products to the EU market, Canada, with its 35 million or so inhabitants, is not in the industry's central focus because its large neighbour has more than ten times as many citizens. The big pharmaceutical giants still have their own sales force in Canada, but the smaller drug manufacturers use companies like Valeo to get the drugs to market.

Covid-19 vaccine in distribution

The special feature of Valeo Pharma is that around 70% of its shares are held by management, employees and insiders. Around CAD 8 million to finance the company has flowed into the cash box from these circles, which should indicate a high level of motivation. Valeo Pharma currently has eight products in its portfolio and six more in the pipeline. In view of the dynamics surrounding Covid-19, it should come as no surprise that the pharmaceutical company's employees will in future also be carrying vaccines against corona viruses in order to flush sales and profits into the cash register.


Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

21. December 2020 | 07:50 CET | by Stefan Feulner

CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!

  • Covid-19

The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.


02. November 2020 | 09:07 CET | by Stefan Feulner

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!


21. October 2020 | 12:42 CET | by Stefan Feulner

BioNTech, Valeo Pharma, Pfizer - Starting signal!

  • Covid-19

Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.